AstraZeneca (AZN) Rating Reiterated by Credit Suisse Group

AstraZeneca (LON:AZN)‘s stock had its “outperform” rating reissued by equities researchers at Credit Suisse Group in a report issued on Tuesday. They presently have a GBX 5,800 ($80.13) target price on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 19.40% from the stock’s current price.

Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($75.99) target price on shares of AstraZeneca in a report on Friday, February 2nd. Goldman Sachs set a GBX 3,800 ($52.50) price target on AstraZeneca and gave the stock a “sell” rating in a report on Monday, February 5th. Barclays reiterated a “top pick” rating and set a GBX 6,300 ($87.04) price target on shares of AstraZeneca in a report on Monday, February 5th. Berenberg Bank increased their price target on AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Monday, March 12th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca currently has an average rating of “Hold” and an average price target of GBX 5,222.52 ($72.15).

Shares of AstraZeneca (LON:AZN) opened at GBX 4,857.50 ($67.11) on Tuesday. The stock has a market capitalization of $61,660.00 and a price-to-earnings ratio of 2,891.37. AstraZeneca has a twelve month low of GBX 4,260 ($58.86) and a twelve month high of GBX 5,520 ($76.26).

In related news, insider Philip A. J. Broadley purchased 415 shares of AstraZeneca stock in a transaction on Friday, February 2nd. The shares were bought at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

TRADEMARK VIOLATION NOTICE: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://sportsperspectives.com/2018/03/22/astrazeneca-azn-rating-reiterated-by-credit-suisse-group.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply